• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Anthracyclines versus No Anthracyclines in the Neoadjuvant Strategy for HER2+ Breast Cancer: Real-World Evidence
CONCLUSION: This study reports real-world evidence showing similar pCR and EFS outcomes with treatment regimens with and without AC and raises awareness of possible overtreatment and long-term toxicity in some patients with HER2+ EBC with the use of AC.PMID:37479867 | DOI:10.1007/s40261-023-01291-6
Source: Clinical Breast Cancer - July 21, 2023 Category: Cancer & Oncology Authors: In ês Soares de Pinho Paulo Luz Lucy Alves Raquel Lopes-Br ás Vanessa Patel Miguel Esperan ça-Martins Lisa Gon çalves Ritas Freitas Diana Sim ão Maria Rold án Galnares Isabel Fernandes Silvia Artacho Criado Salvador Gamez Casado Jose Baena Ca ñada Source Type: research

Chemotherapy-Related Cognitive Impairment in Patients with Breast Cancer Based on Functional Assessment and NIRS Analysis
CONCLUSIONS: Our findings suggest that cognitive impairments in the domain of executive functioning exist among patients with BC who received CT. The results corroborate the hypothesis that CT is an important factor in cognitive impairment in patients with BC, which has been demonstrated by both subjective (PCI) and objective (PVF, SVF, and rSO2) neuropsychological measures. The combination of doxorubicin, cyclophosphamide, and docetaxel induce cognitive impairment.PMID:35566489 | DOI:10.3390/jcm11092363
Source: Clinical Genitourinary Cancer - May 14, 2022 Category: Cancer & Oncology Authors: Noelia Dur án-Gómez Casimiro Ferm ín López-Jurado Marta Nadal-Delgado Demetrio P érez-Civantos Jorge Guerrero-Mart ín Macarena C C áceres Source Type: research

Real-World Treatment Patterns in Metastatic Castration-Resistant Prostate Cancer Across Europe (France, Germany, Italy, Spain, and the United Kingdom) and Japan
CONCLUSION: Real-world mCRPC treatment patterns largely reflected national guidelines. It is expected that guidelines and treatment patterns will change with the development of new treatment options.PMID:35316501 | DOI:10.1007/s12325-022-02073-w
Source: Adv Data - March 22, 2022 Category: Epidemiology Authors: Andrea Leith Jeri Kim Amanda Ribbands Emily Clayton Lingfeng Yang Sameer R Ghate Source Type: research

Beyond cabazitaxel: Late line treatments in metastatic castration resistant prostate cancer: A retrospective multicentre analysis
CONCLUSION: This retrospective multicenter analysis demonstrates the variation in treatment sequences used for mCRPC in the real-world setting. In the absence of high quality, prospective evidence, our results suggest that subsequent treatment choice does not influence survival outcomes and the optimal choice is guided by individual patient and disease-related factors.PMID:35098653 | DOI:10.1111/ajco.13732
Source: Clinical Prostate Cancer - January 31, 2022 Category: Cancer & Oncology Authors: Grace Chazan Angelyn Anton Shirley Wong Julia Shapiro Andrew Weickhardt Arun Azad Edmond M Kwan Lavinia Spain Ashray Gunjur Javier Torres Phillip Parente Francis Parnis Jeffrey Goh Peter Gibbs Ben Tran Source Type: research

Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma
CONCLUSIONS: Our data indicate that the combination of docetaxel and nintedanib can be considered to be an effective treatment for EGFR TKI-resistant EGFR-mutant NSCLC.PMID:34292495 | DOI:10.1007/s12094-021-02661-2
Source: Clinical Lung Cancer - July 22, 2021 Category: Cancer & Oncology Authors: Mariona Riudavets Joaquim Bosch-Barrera Lu ís Cabezón-Gutiérrez Pilar Diz Ta ín Ainhoa Hern ández Miriam Alonso Remei Blanco Elisa G álvez Amelia Insa Xabier Mielgo Teresa Mor án Santiago Ponce Diana Roa Jos é Miguel Sánchez Margarita Majem Source Type: research

Safety and Efficacy of Anti-PD-1 Monoclonal Antibodies in Patients With Relapsed or Refractory Lymphoma: A Meta-Analysis of Prospective Clinic Trails
Conclusions: Nivolumab and pembrolizumab have promising outcomes with tolerable AEs and drug-related deaths in patients with relapsed or refractory lymphoma. Pembrolizumab caused less any grade AEs like fatigue and rash than nivolumab. Patients with HL got better response than NHL. Introduction Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor mainly expressed on activated T cells, natural killer cells, and B cells (Ishida et al., 1992). The PD-L1 and PD-L2 are its known ligands, which interact with PD-1 on T cells and prevent T-cell activation and proliferation. PD-L1 is expressed on macropha...
Source: Frontiers in Pharmacology - April 30, 2019 Category: Drugs & Pharmacology Source Type: research